What does this year’s conference offer the delegates?

We have an extensive and interesting spread of key sessions lined up for the delegates. The scientific program incorporates a wide range of pre-conference CME, invited contributions, free communications, guest lectures, symposia, free papers, poster sessions, orations, panel discussions and clinical pathological sessions. With latest information on the advances in scientific and clinical research that focuses on issues related to practice of Nephrology, all the sessions will add to the knowledge of the participants. There will also be a Symposium on “Palliative care in end-stage kidney disease patients” conducted by the American Society of Nephrology.

What are the common challenges in managing hypertension with CKD?

There is a strong association between CKD and high blood pressure (BP); each can cause or aggravate the other. BP control is an essential part of the care of patients with CKD. BP reduction when achieved using agents that interfere with the renin-angiotensin-aldosterone system (RAAS), can damage kidney function and cause albuminuria.

Hence, it is important to exercise caution while managing high BP in CKD patients. Intensive BP-lowering in patients with CKD calls for the addition of at least one new antihypertensive agent. ARBs seem to be well-tolerated agents and have well-known renoprotective effects.